Granted Patent B2

US 12,496,352 · App. 19/077,324 · Granted Dec 16, 2025

Inventors: Romesh R. Subramanian (Framingham, MA); Mohammed T. Qatanani (Waltham, MA); Timothy Weeden (Waltham, MA); Cody A. Desjardins (Waltham, MA)

Assignee: Dyne Therapeutics, Inc.

A61K47/6807A61K47/60A61K47/6849A61P21/00C07K16/2881C12N15/1137C07K2317/55C07K2317/92C12N2310/11C12N2310/315C12N2310/322C12N2310/3513

Abstract

Claims (21)

1 . A method comprising:

(a) providing an anti-transferrin receptor antibody that binds an extracellular domain of human transferrin receptor protein 1 (TfR1) having an amino acid sequence as set forth in SEQ ID NO: 1, wherein the anti-transferrin receptor antibody does not specifically bind to the transferrin binding site of TfR1;

(b) providing an oligonucleotide that is 15, 16, 17, or 18 nucleotides in length and comprises a region of complementarity that is fully complementary, along a length of at least 14 contiguous nucleotides, to a coding region of a DMPK sequence as set forth in SEQ ID NO: 15, wherein the oligonucleotide is configured to bring about degradation of a DMPK RNA via RNase H mediated degradation, wherein the oligonucleotide comprises a 5′-X-Y-Z-3′ formula, wherein X and Z are flanking regions comprising one or more 2′-modified nucleosides selected from the group consisting of: 2′-O-methyl, 2′-fluoro, 2′-O-methoxyethyl, and 2′,4′-bridged nucleosides, wherein Y is a gap region and each nucleoside in Y is a 2′-deoxyribonucleoside, and wherein the oligonucleotide comprises one or more phosphorothioate internucleoside linkages; and

(c) covalently linking the anti-transferrin receptor antibody to the oligonucleotide to form a complex, wherein the complex comprises the anti-transferrin receptor antibody covalently linked, via a protease-sensitive linker, to the oligonucleotide.

2 . The method of claim 1 , wherein the 5′ end of the oligonucleotide is covalently linked to a lysine in the anti-transferrin receptor antibody via the protease sensitive linker.

3 . The method of claim 1 , wherein the protease-sensitive linker comprises a cleavage site of a lysosomal and/or endosomal protease.

4 . The method of claim 3 , wherein the lysosomal and/or endosomal protease is a cathepsin protease.

5 . The complex of claim 1 , wherein the protease sensitive linker comprises a valine-citrulline sequence.

6 . The method of claim 1 , wherein the protease sensitive linker comprises a triazole obtained by a cycloaddition reaction between an azide and an alkyne.

7 . The method of claim 6 , wherein prior to the cycloaddition reaction, the azide is located on the protease sensitive linker that is covalently linked to the 5′ end of the oligonucleotide and the alkyne is provided in a bicyclononyne moiety, and wherein the protease-sensitive linker further covalently links to the anti-transferrin receptor antibody.

8 . The method of claim 7 , wherein the protease-sensitive linker further comprises one or more polyethylene glycol units.

9 . The method of claim 1 , wherein each nucleotide in X and Z is a 2′-modified nucleoside.

10 . The method of claim 1 , wherein each internucleoside linkage in the oligonucleotide is a phosphorothioate linkage.

11 . The method of claim 1 , wherein the oligonucleotide is 16, 17 or 18 nucleotides in length.

12 . The method of claim 1 , wherein the region of complementarity is fully complementary, along a length of at least 16 contiguous nucleotides, to the coding region of the DMPK sequence.

13 . The method of claim 1 , wherein the anti-transferrin receptor antibody is in the form of a ScFv, Fab fragment, Fab′ fragment, F (ab′) 2 fragment, or Fv fragment.

14 . The method of claim 13 , wherein the anti-transferrin receptor antibody is in the form of a Fab fragment.

15 . The method of claim 1 , wherein the DMPK RNA comprises 38 to 200 repeating CUG units.

16 . The method of claim 1 , wherein the muscle cells are skeletal muscle cells, cardiac muscle cells, or smooth muscle cells.

17 . The method of claim 1 , wherein the DMPK RNA contains a disease-associated repeat sequence in the 3′-UTR that is associated with myotonic dystrophy type 1 (DM1).

18 . The method of claim 1 , wherein the complex is configured for delivering the oligonucleotide into muscle cells.

Assignments (2)

Continuity (10)

References Cited (400)

Cited By (2)

US 12,662,545 US 12,697,394